canin
leishmaniasi
canl
diseas
caus
leishmania
leishmania
chagasi
new
world
protozoan
intracellular
parasit
found
mononuclear
system
mainli
macrophag
vertebr
host
classic
canl
appear
chronic
wast
diseas
generalis
localis
lymphadenopathi
muscular
atrophi
weak
weight
loss
cachexia
anorexia
diarrhoea
vomit
melena
abdomin
pain
lame
polyuria
polydipsi
oliguri
haematuri
coughnos
discharg
epistaxi
rhiniti
onychogryphosi
hepatomegali
splenomegali
addit
cutan
lesion
alopecia
desquam
dri
seborrhoea
hyperpigment
erythema
occur
number
case
control
canl
mani
countri
basic
perform
three
procedur
control
vector
use
residu
action
insecticid
b
cull
elimin
seroposit
dog
detect
epidemiolog
survey
endem
area
c
treatment
human
canin
case
measur
control
drastic
reduc
transmiss
vigor
employ
throughout
year
among
strategi
control
zoonot
viscer
leishmaniasi
cull
seroposit
dog
endem
area
prove
ineffect
expens
impact
human
diseas
limit
social
accept
sever
studi
show
treatment
canin
leishmaniasi
pentaval
antimoni
pentamidin
might
result
clinic
recoveri
remiss
symptom
even
parasitolog
cure
anim
although
relaps
normal
occur
follow
month
use
immunotherapi
treatment
canin
leishmaniasi
repres
new
approach
control
infect
crude
parasit
extract
use
immunotherapi
associ
convent
chemotherapi
clinic
improv
partial
parasitolog
cure
observ
immunochemotherapi
protocol
use
purifi
leishmania
infantum
antigen
l
infantumderiv
fraction
kda
nmethyl
meglumin
antimoni
glucantim
dog
result
parasitolog
cure
month
treatment
contrast
parasitolog
heal
rate
chemotherapi
immunotherapi
alon
respect
result
corrobor
previou
studi
use
murin
model
three
leishmani
recombin
antigen
tsa
leif
extens
test
subunit
base
vaccin
shown
induc
good
protect
murin
nonhuman
primat
model
cutan
leishmaniasi
moreov
leif
compon
shown
therapeut
activ
balbc
model
cutan
leishmaniasi
importantli
antigen
recent
success
use
immunochemotherapeut
protocol
treat
human
mucos
leishmaniasi
three
antigen
present
amastigot
promastigot
form
parasit
highli
conserv
among
leishmania
sp
requisit
ensur
crossspeci
protect
polyprotein
constitut
three
antigen
engin
final
vaccin
candid
name
formul
adjuv
monophosphoryl
lipid
mpl
plu
squalen
mplse
elicit
excel
protect
immun
l
major
infect
murin
model
addit
clinic
investig
dog
immun
recombin
antigen
tsa
leif
formul
adjuv
mplse
induc
almost
exclus
respons
suggest
use
field
trial
canl
howev
studi
demonstr
failur
multisubunit
vaccin
protect
dog
canl
experiment
natur
condit
describ
evalu
immunochemotherapeut
properti
plu
mplse
associ
nmethyl
meglumin
antimoni
glucantim
treat
natur
infect
symptomat
dog
canl
thirti
mongrel
dog
male
femal
age
year
old
natur
infect
l
chagasi
includ
clinic
trial
anim
select
seroepidemiolog
survey
canl
conduct
citi
mont
claro
mina
gerai
state
brazil
dog
includ
trial
typic
clinic
sign
symptomat
viscer
leishmaniasi
present
lymphadenopathi
slight
decreas
weight
opaqu
eye
alopecia
eczema
skin
ulcer
never
receiv
treatment
canl
demonstr
parasit
perform
begin
clinic
trial
use
direct
microscop
examin
giemsa
stain
smear
bone
marrow
aspir
ear
skin
biopsi
bone
marrow
aspir
also
use
isol
parasit
nnnlit
cultur
medium
serolog
test
done
use
immunofluoresc
test
ifat
elisa
use
cutoff
dilut
respect
crude
leishmania
antigen
use
elisa
test
follow
infect
enrol
anim
pretreat
larg
spectrum
anthelmint
drug
endal
plu
scheringplough
cooper
brazil
vaccin
infect
parvoviru
adenoviru
type
distemp
viru
parainfluenza
viru
corona
viru
leptospirosi
recombitek
vaccin
merial
brazil
rabi
viru
ravisini
merial
brazil
dog
fed
commerci
balanc
anim
food
cheroke
pet
brazil
drink
water
provid
ad
libitum
clinic
trial
conduct
kennel
leishmaniasi
experiment
feder
univers
mina
gerai
state
certif
ethic
committe
anim
research
feder
univers
mina
gerai
protocol
trial
perform
agreement
ethic
principl
anim
experiment
follow
guidelin
anim
experiment
nation
institut
health
usa
order
keep
anim
suffer
minimum
convent
drug
nmethyl
meglumin
antimoni
glucantim
aventi
pharma
brazil
use
standard
treatment
vaccin
use
studi
formul
lyophil
corixa
corpor
usa
adjuv
monophosphoryl
lipid
plu
squalen
mplse
corixa
corpor
usa
maintain
c
use
thirti
dog
randomli
alloc
five
group
six
anim
treat
use
follow
protocol
group
mgkgday
nmethyl
meglumin
antimoni
glucantim
b
group
glucantim
concentr
group
plu
g
plu
g
mplse
c
group
plu
mplse
concentr
group
g
mplse
group
placebo
constitut
salin
solut
anim
group
treat
glucantim
two
cycl
day
interv
day
cycl
mgkgday
intramuscularli
inject
immunochemotherapi
perform
administr
three
subcutan
dose
formul
vaccin
day
interv
first
dose
vaccin
administ
anim
receiv
first
inject
drug
treatment
treatment
anim
receiv
mplse
adjuv
mplse
placebo
consist
three
subcutan
inject
interv
dog
follow
day
treatment
assess
clinic
respons
treatment
weekli
clinic
examin
haematolog
biochem
assay
immunolog
evalu
perform
day
treatment
day
parasitolog
examin
cellular
immun
respons
evalu
perform
day
treatment
day
whole
blood
cell
count
wbc
perform
use
haematolog
microcel
counter
coulter
usa
differenti
leukocyt
count
made
use
blood
smear
stain
may
refer
valu
given
jain
appli
interpret
wbc
paramet
amount
total
protein
albumin
alpha
beta
gamma
globulin
fraction
ratio
albuminglobulin
evalu
dog
sera
electrophoresi
celm
paulo
brazil
refer
valu
given
amusategui
et
al
use
calcul
protein
concentr
alanin
amino
transferas
alt
enzym
activ
evalu
liver
function
measur
use
commerci
avail
kit
roch
brazil
level
serum
creatinin
urea
evalu
use
commerci
avail
kit
brazil
refer
valu
interpret
paramet
liver
kidney
function
kaneko
et
al
use
specif
antileishmania
antibodi
evalu
monthli
dog
immunofluoresc
test
ifat
elisa
ifat
perform
use
fluorescein
conjug
anticanin
igg
antiserum
sigma
usa
cutoff
dilut
elisa
use
cutoff
crude
antigen
recombin
perform
accord
et
al
cellular
immun
respons
evalu
lymphocyt
prolifer
assay
briefli
peripher
blood
mononuclear
cell
pbmc
obtain
heparin
blood
sampl
collect
jugular
vein
dog
separ
use
ficollhypaqu
gradient
histopaqu
sigma
cell
per
well
cultur
triplic
well
flatbottom
micropl
stimul
gml
recombin
vaccin
gml
solubl
l
chagasi
antigen
gml
concanavalin
cona
addit
cultur
perform
without
stimul
cell
cultur
final
volum
l
rpmi
sigma
usa
supplement
ui
ml
penicillin
gml
streptomycin
mm
lglutamin
heatinactiv
fc
biolog
industri
kibbutz
beit
haemek
israel
pbmc
incub
day
c
co
puls
last
h
cultur
ci
per
well
h
thymidin
amersham
buck
unit
kingdom
cell
harvest
onto
glass
fibr
filter
model
whatman
usa
hthymidin
incorpor
count
use
liquid
scintil
beta
counter
titertek
cell
harvest
flow
laboratori
usa
prolif
respons
express
stimul
index
si
repres
ratio
mean
cpm
obtain
stimul
cultur
cpm
unstimul
cultur
bone
marrow
punctur
perform
intercondin
fossa
tibia
previous
procedur
dog
anaesthetis
acepromazin
acepran
mgkg
sodium
thiopent
thionembut
mgkg
bone
marrow
result
express
number
observ
anim
percentag
nonobserv
b
dead
anim
classifi
oligosymptomat
glucantim
alon
glucantim
mplse
symptomat
mplse
mplse
placebo
end
studi
aspir
cultur
duplic
tube
contain
nnnlit
medium
tube
incub
c
examin
everi
day
day
discard
neg
ear
skin
biopsi
collect
small
pinch
ear
lobe
obtain
scalpel
smear
bone
marrow
aspir
skin
biopsi
giemsa
stain
submit
microscop
examin
assess
whether
treatment
mplse
glucantim
immunochemotherapeut
protocol
might
block
transmiss
vector
xenodiagnosi
perform
specif
group
end
studi
dog
sedat
mgkg
acepromazin
acepran
univet
sa
paulo
brazil
twenti
femal
laboratori
rear
lutzomyia
longipalpi
place
round
plastic
box
cm
diamet
cm
height
open
side
cover
finemesh
nylon
screen
place
skin
intern
ear
dog
roll
set
cover
piec
black
fabric
achiev
ideal
condit
stimul
feed
min
sand
fli
transfer
hold
cage
kept
temperatur
c
rel
air
humid
fifth
day
blood
meal
genom
dna
pcr
extract
femal
aliv
accord
michalski
et
al
surviv
rate
death
risk
anim
group
analyz
kaplanmai
test
cox
model
test
respect
statist
analysi
carri
use
tstudent
test
nonparametr
test
kruskallw
tukey
test
kaplanmai
test
cox
model
analys
perform
use
softwar
spss
pc
anim
receiv
either
glucantim
alon
glucantim
plu
mplse
improv
clinic
respons
howev
anim
receiv
glucantim
plu
mplse
show
better
clinic
respons
treatment
contrast
anim
group
worsen
symptom
end
studi
seven
dog
die
treatment
two
group
glucantim
one
group
glucantim
mplse
one
group
mplse
three
dog
group
placebo
dead
anim
consid
oligosymptomat
glucantim
alon
glucantim
mplse
symptomat
mplse
mplse
placebo
end
studi
also
end
studi
remain
dog
reclassifi
asymptomat
olygosymptomat
symptomat
accord
mancianti
et
al
result
shown
tabl
haematolog
analysi
show
signific
differ
valu
neutrophil
eosinophil
among
group
studi
slight
decreas
number
monocyt
observ
anim
treat
glucantim
chemo
immunochemotherapi
group
suggest
advers
effect
drug
howev
reduct
signific
compar
proper
refer
valu
increas
lymphocyt
count
also
seen
group
end
studi
signific
compar
baselin
valu
day
treatment
statist
signific
increas
p
valu
red
blood
cell
rbc
demonstr
anim
receiv
either
chemo
immunochemotherapi
convers
anim
remain
group
present
progress
anaemia
studi
increas
albumin
valu
compar
refer
valu
gdl
demonstr
anim
treat
chemo
immunochemotherapi
time
evalu
contrast
signific
reduct
paramet
observ
remain
group
valu
globulin
gdl
globulin
gdl
remain
within
normal
refer
valu
studi
group
end
studi
level
globulin
reach
normal
valu
gdl
chemo
immunochemotherapi
group
anim
other
group
hypergammaglobulinemia
indic
renal
function
level
creatinin
urea
retain
well
liver
function
evalu
enzym
alanin
amino
transferas
statist
differ
among
group
time
evalu
cure
anim
number
return
valu
renal
liver
function
normal
refer
paramet
criterion
inclus
studi
anim
posit
parasitolog
test
either
direct
microscopi
examin
bone
marrow
smear
skin
biopsi
stain
giemsa
bone
marrow
cultur
nnnlit
medium
end
studi
convent
parasitolog
test
smear
cultur
neg
anim
group
contrast
anim
group
remain
posit
ascertain
neg
parasit
burden
group
xenodiagnosi
detect
pcr
also
perform
result
indic
anim
group
posit
pcr
contrast
two
dog
group
neg
dog
consid
cure
fig
tabl
tabl
illustr
rate
group
dog
end
clinic
observ
expect
surviv
rate
lowest
control
salin
group
group
treat
glucantim
group
surviv
rate
respect
surviv
adjuv
group
mplse
note
observ
anim
die
surviv
group
treat
immunotherapeut
protocol
plu
mplse
surviv
probabl
time
therapeut
intervent
estim
use
kaplanmai
analysi
day
probabl
group
death
period
time
end
studi
surviv
probabl
decreas
anim
treat
glucantim
alon
anim
treat
glucantim
plu
protocol
anim
treat
placebo
anim
treat
adjuv
alon
surviv
probabl
end
studi
interestingli
surviv
probabl
anim
plu
mplse
immunotherapi
fig
antibodi
respons
anim
treat
glucantim
alon
glucantim
mplse
present
signific
reduct
p
specif
antibodi
titter
end
studi
determin
ifat
elisa
crude
antigen
elisa
antigen
tabl
contrast
dog
treat
vaccin
alon
mplse
alon
placebo
show
increas
specif
antibodi
titter
howev
despit
reduct
antibodi
titer
former
two
group
antibodi
titer
remain
specifi
posit
cutoff
two
anim
group
show
neg
result
serolog
test
day
prolifer
pbmc
stimul
leishmani
antigen
crude
l
chagasi
extract
antigen
mitogen
concanavalin
con
use
investig
cell
respons
dog
enrol
studi
prolifer
assay
evalu
day
enrol
end
studi
day
pbmc
anim
two
group
treat
vaccin
respond
better
vitro
stimula
tion
antigen
three
group
fig
expect
anim
receiv
vaccin
present
higher
cell
prolif
respons
observ
group
treat
adjuv
placebo
p
similar
tendenc
also
observ
respons
l
chagasi
crude
antigen
statist
signific
achiev
respons
mitogen
con
high
placebo
group
indic
known
immunosuppress
cell
respons
untreat
viscer
leishmaniasi
use
chemotherapi
base
pentaval
antimoni
glucantim
introduc
year
ago
viscer
leishmaniasi
still
constitut
first
drug
choic
treat
diseas
caus
leishmania
howev
recent
develop
drug
resist
associ
variat
sensit
leishmania
speci
drug
strongli
reveal
need
develop
redevelop
altern
treatment
might
replac
complement
valu
valu
express
mean
antibodi
titer
group
day
therapi
standard
deviat
n
number
dog
evalu
lymphoprolif
respons
dog
differ
protocol
treatment
end
studi
day
specif
leishmaniacel
prolif
respons
evalu
use
crude
l
chagasi
antigen
extract
left
yaxi
mitogen
respons
assess
stimul
concanavalin
cona
right
yaxi
dot
repres
individu
valu
anim
bar
repres
median
valu
group
statist
signific
differ
observ
anim
receiv
remain
group
p
also
anim
treat
vaccin
comparison
control
adjuv
placebo
group
p
exist
newer
therapeut
drug
inde
drug
combin
treat
vl
test
promis
result
treat
leishmaniasi
caus
drug
resist
similarli
combin
drug
vaccin
even
vaccin
alon
success
use
treat
american
cutan
leishmaniasi
past
year
low
number
recurr
case
combin
antileishmania
treatment
use
vaccin
drug
would
enhanc
drug
efficaci
stimul
host
immun
respons
result
therapeut
har
cellular
immun
protect
therapeut
use
recombin
antigen
standard
drug
treatment
leishmaniasi
would
advantag
due
wellcharacter
natur
requir
meet
scientif
regulatori
standard
inde
leishmani
recombin
antigen
tsa
leif
combin
cytokin
granulocyt
monocyt
coloni
stimul
factor
gmcsf
use
adjuv
recent
success
use
treat
human
mucos
leishmaniasi
common
drug
use
treatment
canin
leishmaniasi
pentaval
antimoni
destroy
parasit
inhibit
two
leishmani
essenti
enzym
phosphofructokinas
dehydrogenas
pyruv
need
glycolyt
fatti
acid
oxid
simultan
dog
chemotherapi
use
pentaval
antimoni
mostli
unsuccess
mani
occas
reportedli
caus
exacerb
diseas
although
major
clinic
sign
diseas
disappear
treatment
treat
anim
may
present
good
gener
health
statu
might
indic
complet
absenc
parasit
spleen
bone
marrow
skin
inde
mani
treat
anim
remain
infect
sand
fli
sever
month
posttreat
clinic
trial
l
chagasi
natur
infect
symptomat
dog
submit
immunochemotherapi
standard
pentaval
antimoni
drug
glucantim
associ
recombin
vaccin
formul
adjuv
mplse
treatment
glucantim
ident
dose
use
mancianti
et
al
associ
mplse
result
clinic
improv
infect
anim
associ
normal
biochem
haematolog
paramet
reduct
antileishmania
antibodi
result
resembl
initi
immunochemotherapi
canl
use
glucantim
plu
leishmani
crude
extract
antigen
end
studi
day
two
dog
group
clinic
cure
convers
parasitolog
immunolog
paramet
also
accord
clinic
classif
mancianti
et
al
moreov
xenodiagnosi
techniqu
perform
identif
infect
phlebotomin
sand
fli
potenti
transmiss
parasit
anim
treat
glucantim
mplse
indic
clinic
cure
dog
also
pcr
neg
hand
transmiss
block
effect
confer
immunochemotherapeut
protocol
still
remain
uncertain
sinc
anim
treat
protocol
also
present
posit
xenodiagnosi
moreov
lack
data
anim
treat
remain
protocol
make
difficult
assess
whether
propos
treatment
abl
effect
avoid
reduc
transmiss
invertebr
host
viscer
leishmaniasi
treatment
typic
consid
success
clinic
sign
disappear
result
haematolog
serum
biochem
analys
within
refer
rang
clinic
recoveri
observ
group
glucantim
mplse
glucantim
alon
could
relat
use
drug
immunochemotherapi
cohort
reduc
number
death
higher
surviv
probabl
higher
specif
cellular
reactiv
leishmani
antigen
comparison
treatment
glucantim
alon
resist
leishmaniasi
well
known
mediat
cellmedi
protect
immun
respons
specif
leishmania
antigen
although
clinic
manifest
leishmania
infect
differ
immunolog
pictur
patient
acut
viscer
leishmaniasi
lack
cell
reactiv
particularli
specif
antibodi
titer
high
cell
defici
manifest
vitro
failur
lymphocyt
prolifer
stimul
parasit
antigen
usual
patient
becom
respons
resolut
symptom
therefor
cell
reactiv
shown
either
vitro
eg
lymphocyt
prolif
respons
leishmania
antigen
vivo
eg
delay
hypersensit
leishmani
antigen
import
surrog
protect
leishmaniasi
consequ
treatment
provid
clinic
recoveri
restor
least
partial
cell
reactiv
leishmani
compon
highli
desir
henc
canl
vaccin
promot
least
partial
protect
trigger
type
immun
respons
eventu
might
lead
protect
diseas
also
consid
futur
protocol
immunochemotherapi
infect
dog
way
recent
report
heterolog
primeboost
vaccin
nonrepl
vaccinia
recombin
vector
express
lack
confer
protect
canin
viscer
leishmaniasi
correl
absenc
viscer
leishmaniasi
symptom
lower
parasitespecif
antibodi
higher
degre
cell
activ
parasit
organ
higher
synthesi
cytokin
addit
long
last
protect
fucos
mannos
ligand
fml
vaccin
leishmun
demonstr
also
effect
immunotherapi
viscer
leishmaniasi
asymptomat
symptomat
infect
dog
treatment
symptomat
dog
leishmun
vaccin
reduc
clinic
symptom
evid
parasit
modul
outcom
infect
block
transmiss
parasit
phlebotomin
three
leishmani
antigen
tsa
lmstil
leif
select
develop
subunit
vaccin
consid
promis
candid
vaccin
therapi
protocol
base
demonstr
abil
induc
protect
balbc
mous
model
l
major
either
prophylact
tsa
lmstil
therapeut
leif
applic
hand
chose
use
monophosphoryl
lipid
mpl
adjuv
strong
immunostimulatori
effect
innat
immun
system
direct
activ
antigen
present
cell
produc
gmcsf
result
enhanc
phagocytosi
microbicid
activ
addit
formul
antigen
plu
mplse
previous
use
dog
shown
highli
effici
induc
power
respons
recombin
antigen
although
failur
induc
protect
immun
dog
final
import
point
deserv
investig
observ
death
occur
group
anim
submit
immunotherapeut
protocol
although
number
anim
group
larg
enough
warrant
statist
analysi
intrigu
result
unfortun
protocol
alon
suffici
lead
total
parasit
elimin
occur
two
anim
group
treat
glucantim
howev
result
togeth
suggest
immunotherapi
import
adjunct
anticanl
therapeut
protocol
use
lower
dose
glucantim
word
immunotherapi
import
factor
may
favour
administr
much
lower
concentr
glucantim
administ
current
protocol
also
use
current
studi
well
known
glucantim
seriou
side
effect
includ
death
present
studi
use
cox
statist
analysi
base
serum
level
albumin
gamma
globulin
creatinin
defin
anim
treat
glucantim
instantan
death
risk
time
higher
anim
treatment
therefor
institut
immunochemotherapeut
protocol
constitut
togeth
glucantim
may
help
defin
new
scheme
lower
dose
latter
consequ
minim
risk
death
interest
possibl
deserv
investig
conclus
present
studi
show
combin
standard
drug
treat
leishmaniasi
mplse
might
improv
current
therapi
canl
sever
former
studi
describ
immunochemotherapi
protocol
use
whole
parasit
vaccin
immunogen
compon
howev
use
multipl
recombin
antigen
deliv
singl
recombin
polyprotein
would
result
better
approach
immunochemotherapi
repres
higher
standard
product
simplifi
manufactur
process
attract
distribut
develop
countri
due
associ
reduc
cost
approach
also
repres
valid
altern
treatment
case
convent
chemotherapi
effect
